Book Your Room for ACE 2025 Now!

Start planning for the Michigan Pharmacists Association (MPA) 2025 Annual Convention & Exposition April 11-13, 2025, at the Grand Traverse Resort and Spa just outside of Traverse City! Information on registration will become available later this year, but it's not too early to block off your calendars as pharmacy's biggest continuing education event in Michigan takes its show on the road. You can book your room now by clicking the button below or scanning the QR code above.

MPA is encouraging guests to make ACE 2025 their Michigan "staycation." Whether it's a round of golf or exploring the sights and sounds of the beautiful Traverse City area, there are limitless activities at ACE 2025.

- ANTIMICROBIAL STEWARDSHIP -

What to Know for the Upcoming RSV Season for Pediatrics

Christine Wu, Pharm.D., PGY-1 resident, and Daniel Riggsbee, Pharm.D., BCPS, BCPPS, University of Michigan Health 

Respiratory syncytial virus is the leading cause of infant hospitalizations in the United States and may cause serious illness – and, rarely, death – in infants and young children.¹ Almost all children are infected with RSV by their third year of life and repeat infections can occur at any age.² In Michigan, RSV typically begins circulating in the community in October, peaks in January and concludes in March.³ Supportive care remains the mainstay of therapy, as no antiviral agent has demonstrated reliable clinical effectiveness for treatment.⁴ Palivizumab, previously the only preventative agent for RSV lower respiratory tract infection (LRTI), has numerous limitations. In 2023, two agents, RSVpreF vaccine (Abrysvo) and nirsevimab (Beyfortus), received U.S. Food and Drug Administration approval for preventing RSV LRTI in infants.⁵

RSVpreF is an RSV preF A and B subunit recombinant vaccine indicated for the protection of infants from RSV LRTI. It provides passive immunity through maternal antibodies produced against the RSV antigens and is expected to offer protection from birth through 6 months old.⁶ To ensure protection through the newborn’s first RSV season, one-time vaccination is recommended between weeks 32 and 36 of pregnancy during September through January of the following year.⁷  

Nirsevimab is a human monoclonal antibody indicated for the prevention of RSV LRTI in infants and high-risk children.⁸ Nirsevimab is an intramuscular injection administered during the first week of life, though administration may be deferred until discharge from an extended birth hospitalization. Nirsevimab is indicated for all infants less than 8 months old born during or entering their first RSV season, as well as for children ages 8 to 19 months with risk factors or severe RSV disease entering their second RSV season.⁹ Administering nirsevimab no earlier than October ensures protection throughout the typical RSV season.⁸

Historically, palivizumab (Synagis) was the only preventative agent for RSV LRTI, but has shown efficacy only in a limited population with risk factors for severe RSV disease, such as patients with a history of congenital heart disease or premature birth.^10-11 Its 30-day duration, monthly administration with a 60-minute infusion and cost have also greatly limited the utility of palivizumab.¹² 

RSVpreF and nirsevimab both meet the need of protection for babies without risk factors for severe RSV LRTI, offering protection for the full RSV season. The Centers for Disease Control currently recommends either method of protection. Infants born more than 14 days after maternal RSV vaccination generally do not require nirsevimab. However, nirsevimab may be considered based on the clinical judgment of the healthcare provider; the potential incremental benefit of administration is warranted, such as birth within 14 days of vaccination or birth from mothers who may not mount an adequate immune response.^8-13 

Despite similar safety and efficacy profiles for both prevention methods, a few considerations are noteworthy. Administering the RSVpreF vaccine between weeks 24 and 36 of pregnancy has been linked to an increased risk of preterm birth, as well as conditions associated with preterm birth such as pre-eclampsia, a low birth weight of less than 5.5 pounds and jaundice in newborns.⁷ Consequently, the FDA has approved the use of this vaccine during weeks 32 through 36 of pregnancy to mitigate the risk. Despite the risk, the maternal vaccine provides immediate protection from the time of birth. 

Limited patient access in the 2023-2024 RSV season during a nationwide shortage prevented many from receiving nirsevimab within the recommended time of the first week of life.^{8, 14-15} No shortage is anticipated in the 2024-2025 season. Providers may use shared decision making when deciding between modes of protection.¹⁶ Palivizumab remains a viable option for protection for patients with risk factors for severe disease in cases where nirsevimab is unavailable.

Pregnant people can receive RSV, Tdap, COVID-19 and influenza vaccines simultaneously. Infants may receive nirsevimab alongside other routine childhood immunizations. Most children will require only one dose of nirsevimab in their first year of life. However, young children with risk factors for severe RSV LRTI – including severely immunocompromised, American Indian or Alaska Native descent, cystic fibrosis with severe lung disease or weight-for-length less than the 10th percentile and chronic lung disease of prematurity requiring medical support in the six months prior to the second RSV season – should receive a second dose for continued protection during their second RSV season.⁹ 

References

1. Healthcare Providers: RSV Immunization for Children 19 months and younger. Centers for Disease Control and Prevention. September 28, 2023. Accessed Aug. 3, 2024. https://www.cdc.gov/vaccines/vpd/rsv/hcp/child.html.  
2. How RSV spreads. Centers for Disease Control and Prevention. May 30, 2024. Accessed August 3, 2024. https://www.cdc.gov/rsv/causes/index.html.  
3. Immunizations to protect infants. Centers for Disease Control and Prevention. June 5, 2024. Accessed August 3, 2024. https://www.cdc.gov/rsv/vaccines/protect-infants.html.  
4. Zhang XL, Zhang X, Hua W, Xie ZD, Liu HM, Zhang HL, Chen BQ, Chen Y, Sun X, Xu Y, Shu SN, Zhao SY, Shang YX, Cao L, Jia YH, Lin LN, Li J, Hao CL, Dong XY, Lin DJ, Xu HM, Zhao DY, Zeng M, Chen ZM, Huang LS. Expert consensus on the diagnosis, treatment, and prevention of respiratory syncytial virus infections in children. World J Pediatr. 2024 Jan;20(1):11-25. doi: 10.1007/s12519-023-00777-9. Epub 2023 Dec 8. Erratum in: World J Pediatr. 2024 Feb 25. doi: 10.1007/s12519-023-00792-w. PMID: 38064012; PMCID: PMC10828005.
5. RSV (respiratory syncytial virus) immunizations. Centers for Disease Control and Prevention. July 3, 2024. Accessed Aug. 3, 2024. https://www.cdc.gov/vaccines/vpd/rsv/index.html.  
6. Healthcare Providers: RSV vaccination for pregnant people. Centers for Disease Control and Prevention. Sept. 29, 2023. Accessed Aug. 4, 2024. https://www.cdc.gov/vaccines/vpd/rsv/hcp/pregnant-people.html. 
7. Fleming-Dutra KE, Jones JM, Roper LE, et al. Use of e Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(41):1115-1122. Published 2023 Oct 13. doi:10.15585/mmwr.mm7241e1
8. Nirsevimab frequently asked questions. American Academy of Pediatrics. July 31, 2024. Accessed Aug. 4, 2024. https://www.aap.org/en/patient-care/respiratory-syncytial-virus-rsv-prevention/nirsevimab-frequently-asked-questions/. 
9. AAP Recommendations for the Prevention of RSV Disease in Infants and Children. American Academy of Pediatrics . Feb. 21, 2024. Accessed Aug. 9, 2024. https://publications.aap.org/redbook/resources/25379/AAP-Recommendations-for-the-Prevention-of-RSV. 
10. 10. MedImmune, LLC. Palivizumab (Synagis) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103770s5185lbl.pdf. Revised March 2014. Accessed Aug. 9, 2024. 
11. Committee on Infectious Disease and Bronchiolitis Guideline Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 2014; 134:415-420.
12. Gutfraind A, Galvani AP, Meyers LA. Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection. JAMA Pediatr. 2015 Apr;169(4):341-8. doi: 10.1001/jamapediatrics.2014.3804. PMID: 25706618; PMCID: PMC4391881.
13. MedImmune, LLC. Palivizumab (Synagis) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/palimed102302LB.pdf. Revised December 1999. Accessed Aug. 9, 2024. 
14. Jones JM, Fleming-Dutra KE, Prill MM, et al. Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices – United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(34):920-925. Published 2023 Aug 25. doi:10.15585/mmwr.mm7234a4
15. Esposito S, Abu-Raya B, Bonanni P, et al. Coadministration of Anti-Viral Monoclonal Antibodies With Routine Pediatric Vaccines and Implications for Nirsevimab Use: A White Paper. Front Immunol. 2021;12:708939. Published 2021 Aug 11. doi:10.3389/fimmu.2021.708939
16. Updated Guidance for Healthcare Providers on Increased Supply of Nirsevimab to Protect Young Children from Severe Respiratory Syncytial Virus (RSV) during the 2023-2024 Respiratory Virus Season . Centers for Disease Control and Prevention. Jan. 5, 2024. Accessed Aug. 19, 2024. https://emergency.cdc.gov/newsletters/coca/2024/010524a.html.

- BOARD UPDATE -

Pharmacy Learners in Transitions of Care: Essential Contributions Without Busy Work

 Stacy Brousseau, Pharm.D., BCPS; emergency medicine clinical pharmacist, Bronson Methodist Hospital; MSHP president-elect

The complexity of transitions of care in the hospital setting emphasizes the need for meticulous planning and execution. By leveraging the skills and enthusiasm of pharmacy learners, integrating students and residents into this process offers a dual benefit: enhancing patient outcomes while also providing valuable educational experiences. Embracing the principle of essentialism – focusing on what truly matters —ensures that learners are engaged in meaningful activities rather than busy work.

Transitions of care involve critical tasks such as medication reconciliation, patient education, multidisciplinary collaboration and discharge planning. Given the high stakes involved, it's essential that pharmacy learners are not simply assigned tasks that keep them occupied but rather engaged in activities that directly impact patient care and reflect their training needs. Essentialism in this context means prioritizing tasks that align with both the learners’ educational goals and the hospital's objectives for effective transitions.

Medication Reconciliation

Pharmacy learners should be involved in medication reconciliation with a clear understanding of its importance and impact. Rather than assigning them mundane data entry or simple verification tasks, they should actively participate in identifying discrepancies with the reconciled medications, evaluating their clinical significance and making recommendations for resolution. This approach ensures that learners are not just filling gaps but are engaging deeply with the medication management process.

There are endless studies showing the positive impact of pharmacy learners on medication reconciliation.¹ One study found that in 27% of emergency department (ED) admissions, pharmacy students were able to determine that the patient’s main complaint was related to a medication which ED triage failed to identify.² Another study compared pharmacy students’ medication reconciliation to that of physicians and nurses, and found that pharmacy students not only identified significantly more discrepancies, but also made multiple interventions based on the discrepancies they found.³ Of those interventions, more than 50% were deemed to have significant impact.

Pharmacy learners, under the guidance of experienced preceptors, can perform detailed medication reviews, update medication lists and communicate critical changes to the health care team, ensuring that patients receive accurate and safe medication regimens during their transitions of care.

Patient Education

The role of pharmacy learners in patient and caregiver education should be structured to maximize engagement and learning. Rather than simply providing information or performing generic tasks, learners should be involved in creating tailored educational materials, conducting interactive sessions, and addressing specific patient concerns. This involvement ensures that their efforts are impactful and relevant, rather than just an exercise in completion. Pharmacy learners can provide personalized education on medication usage, potential side effects, and lifestyle modifications – all of which will enhance patient engagement and promote better health outcomes. This demonstrates the value of engaging learners in valuable, rather than superficial, educational activities.

Discharge Planning

Involvement in discharge planning should focus on the most critical aspects of the transition from hospital to home, such as developing comprehensive discharge instructions and follow-up plans, as well as providing handoff to ambulatory care teams. Pharmacy learners can engage in creating actionable plans and addressing potential issues, rather than just handling routine documentation. This approach ensures that their involvement has a direct impact on patient outcomes and provides a meaningful learning experience.

MSHP’s own Shelby Kelsh, a professor at Ferris State University College of Pharmacy, was the lead author on a study published in 2021 which investigated patient outcomes of a student pharmacist-led transitions of care service. In this study, student pharmacists followed the patients’ inpatient care, reviewed discharge orders and provided discharge education, provided handoff to the ambulatory care pharmacist, and participated in outpatient follow-up at the primary care provider office. The investigators found that the student pharmacist-led transitions of care service significantly reduced 30-day hospital readmissions by 13.1% compared with standard of care.⁴ This underscores the importance of engaging learners in essential, impactful tasks rather than peripheral activities.

Abandoning Busy Work

In 2024, the involvement of pharmacy residents and students in transitions of care is a strategic approach to enhance patient outcomes and improve pharmacy practice. By adhering to the principle of essentialism and focusing on meaningful contributions, we can ensure that learners are engaged in tasks that have a significant impact. By focusing on these essential roles and avoiding busy work, we can address the challenges of transitions of care while also supporting the professional growth of pharmacy students and residents.

References

1. Champion H, Loosen J, Kennelty K. Pharmacy Students and Pharmacy Technicians in Medication Reconciliation: A Review of the Current Literature. J Pharm Pract. 2019 Apr;32(2):207-218.
2. Shepherd G, Schwartz RB. Frequency of incomplete medication histories obtained at triage. Am J Health Syst Pharm. 2009;66(1):65–69.
3. Lancaster JW, Grgurich PE. Impact of student pharmacists on the medication reconciliation process in high-risk hospitalized general medicine patients. Am J Pharm Educ. 2014;78(2):34.
4. Kelsh S, de Voest M, Stout M. Improving 30-day readmissions: Student pharmacists' role in transitions of care. J Am Pharm Assoc. 2021 Jul-Aug;61(4):e233-e236

- MEMBER SPOTLIGHT -

Erin Munsel

Clinical pharmacist specialist – Neonatal Intensive Care, CS Mott Children’s Hospital; PGY2 Pediatric Residency Program director, adjunct clinical instructor, University of Michigan College of Pharmacy

Employer: University of Michigan Health

Member Since: 2016

Describe Your Role/Day in the Life: My day begins with patient care, including chart review and patient-centered rounds on approximately 60 patients in the Brandon NICU at Mott Children’s Hospital. I have extremely strong relationships with the providers and nurses in my unit and am fortunate to have a great deal of independence as it relates to medication management. Following rounds, my afternoons are fairly varied with a mix of meetings, precepting, projects, research and management of the PGY2 pediatric residency program.

Why You’re an MSHP/MPA Member: Being a member of MSHP and MPA affords me the opportunity to interact with pharmacists across the state in a variety of practice areas. These interactions at events such as MSHP Committee Days often reignite my interest/passion and spark ideas that can sometimes be dulled in the day-to-day routine. The networking/collaboration afforded by the organization is my primary driver for career-long membership. Involvement in national organizations is something that always seemed daunting in terms of ability to make meaningful impact close to home. MSHP gives me the opportunity to be involved and advocate for pharmacists and technicians working around me every day. 

Recent Accomplishments: Last October I was able to present as part of a panel at the MSHP Annual Meeting on navigating the transition from resident to new practitioner. This helped to spark interest in presenting at other conferences, including a presentation at the State of Michigan Association of Neonatal Nurses on neonatal sedation and analgesia. I am also currently entering my second year as co-chair of the MSHP Residency Committee.

How MSHP/MPA Has Helped You Achieve Any Accomplishments: MSHP/MPA has been instrumental in helping to identify new areas of interest outside of my primary clinical practice area, allowing me to build upon my skills as a residency program director as part of the MSHP Residency Committee, and providing opportunities to be involved with the profession and pharmacy leaders outside of my institution.

- MEMBERSHIP -

Getting Tech-nical: Promoting Technician Advancement

Julie Schmidt, Pharm.D., BCPS; cardiology clinical pharmacist, Bronson Methodist Hospital, Kalamazoo; MSHP director; Membership Committee board liaison

As part of my duties as the MSHP board liaison to the Membership Committee, one of the tasks I was assigned this year was to write a technician-focused article for the MSHP Monitor. I wanted to know exactly who my audience would be, so I emailed MPA Chief Strategy Officer Bryan Freeman to figure out some numbers. I knew the number of technicians in MSHP was low, but I was taken aback to learn that we currently have one (!) technician member in MSHP.  

There are currently 495 MSHP members and 188 MSPT members. My fellow MSHP members, we have work to do. Previously MPA members could only choose one practice section, so it was natural for technicians to gravitate to MSPT. This has since been updated and now you can pick more than one practice section (i.e. a technician can now pick MSPT and MSHP).

Why should we recruit more technicians? Why should technicians join MSHP? What are we currently doing to support technicians? I think it is extremely important to note that for pharmacists to practice at the top of their license, pharmacy technicians need to be able to practice at the top of theirs.  

It’s fitting that one of MSHP’s goals in its current strategic plan is technician advancement with the objective to promote health-system pharmacy technicians as a career. One of the charges for the Organizational Affairs Committee this year was to “identify and promote best practices for health-system pharmacy technician recruitment and retention.” This charge will carry into next year as well. During committee days this year, the following tactics were discussed to achieve the charge: 

• Use the MPA directory to circulate a survey to health-system pharmacy technicians
• Engage health-system leadership in discussion around their tactics
• Use MPA CEO Mark Glasper’s connections with PTCB
• Utilize and disseminate whitepaper previously written on this topic,
• Hold a raffle/drawing for membership and Amazon gift cards

At our recent strategic planning meeting in September, there was great discussion regarding advancement of pharmacy technicians. We discussed working more with MSPT to gather what their needs are. We could also create a meeting or forum specific to technicians to increase networking opportunities. 

One interesting thought was should MPA and MSHP be advocating that an associate degree be required for pharmacy technicians? The reasoning behind this was that for some other professions (such as radiology technicians), having an associate degree improved salaries and decreased shortages, both issues we know currently affect technicians. Based on the discussion at the strategic planning meeting, MSHP President-elect Stacy Brousseau created potential technician-focused charges for various committees to work on in 2025. These charges were finalized at the October board meeting:

1. Identify new opportunities outside of medication histories to elevate technician practice.
2. Develop a promotional flyer for pharmacy technicians which outlines member benefits of MSHP and MSPT to be shared with health systems.
3. Investigate ways MSHP can support MSPT in order to help pharmacy technician career development and advocacy for their profession.
4. Develop a best practice recommendation for training pharmacy technicians on “Tech Check Tech” which health-systems in Michigan can utilize. Determine the best avenue for promoting this recommendation. Consider required competencies or continuing education for technicians who receive this training.
5. Promote best practices for health-system pharmacy technician recruitment and retention. Focus on challenges that Michigan health systems are facing.

In addition to what MSHP is doing to advance the technician profession, I wanted to look at what the American Society of Health-System Pharmacists are doing as well. ASHP has an entire section on their website called “Featured Resources for Pharmacy Technicians.” This section includes training resources, a job board, links to continuing education and podcasts. In 2023, ASHP created “The Pharmacy Technician Society” (TPTS) to support technician career advancement and professionalism. The ASHP website describes TPTS as a “a new organization led by and comprised of pharmacy technicians to provide critical advocacy and advancement opportunities for the pharmacy technician workforce in all patient care settings.” Benefits of joining TPTS include advocacy for technician advancement, career development, continuing education, networking, publication and standards for the professional practice of pharmacy technicians.

The technician-focused areas that ASHP is currently working on are:

1. Ensure that appropriately supervised pharmacy technicians are able to practice to the height of their training and education when providing pharmacy services.
2. Provide opportunities for on-going professional development and career advancement for pharmacy technicians.
3. Promote and highlight the many and varied roles of pharmacy technicians as valuable contributors to healthcare delivery.
4. Enhance recruitment and retention of qualified pharmacy technicians.
5. Urge compensation for pharmacy technicians commensurate with advanced roles and responsibilities.

There is absolutely room for improvement in recruiting technicians to MSHP. We are and will be doing excellent work towards technician advancement and promoting health-system technicians as a career. I would encourage us to work with our MSPT colleagues this year to gather their feedback and encourage them to also join MSHP.

- ORGANIZATIONAL AFFAIRS -

MPA House of Delegates FAQ

Ryan Bickel, Pharm.D., MHA, FASHP; MSHP Organizational Affairs Committee; director of pharmacy, Ascension Borgess Hospital

The MPA House of Delegates (HOD) is the policy-making body of the Association. Some of its primary functions include voting on MPA bylaw changes, acting upon resolutions of policy and approving the slate of candidates for the Executive Board. This can be confusing if you have never served as a delegate or observed the House in session. The following frequently asked questions should help clarify some of the perplexity.

What is a resolution?

A resolution is a recommendation to be considered for action by the Association. Any MPA member or delegate can present a resolution to the House for consideration. Resolutions follow a specific format consisting of the following:

• Title
• Name of the member introducing the resolution
• Component organization being represented, if applicable
• Body – background information
• “Where as” – comments supporting the recommendation
• “Therefore, be it Resolved” – action statement, indicating what you want the Association to do

Resolutions must be submitted to the secretary of the House at least 90 days prior to the HOD session, which is held during the MPA Annual Convention & Exposition (ACE).

What happens to a resolution once submitted?

Here is a general “life cycle” of resolutions:

• Resolutions are presented to the delegates during the session.  
• Delegates discuss the “Therefore, be it Resolved” portion of each resolution and have the opportunity to adopt, adopt as amended in the resolved portion, or reject a resolution.
• Resolutions that are enrolled or enrolled as amended are forwarded to the MPA Executive Board.
• Executive Board assigns the resolution to various MPA committees and sections for feedback.
• Executive Board reviews the feedback and makes recommendations regarding the resolution to the HOD in the fall. Recommendations take into consideration other Association priorities; benefit to membership, public health and the pharmacy profession; and resources of the Association.
• A ballot is provided to the delegates to decide whether to accept the Executive Board’s recommendations. If accepted, the resolution is adopted and becomes policy of MPA.
• Based on current status and priorities of the Association, resources are devoted to implementing the policy.
• Adopted resolutions are reviewed by the HOD after three years to determine if they should be continued as Association policy or “sunset.”

How do I become a delegate?

The House is composed of delegates from local associations, MSHP regional societies, affiliate chapters and Executive Board members. Most MSHP delegates represent one of the regional societies (CAPA, NMHSP, SMSHP and WMSHP) or a local association. Each recognized component organization shall be entitled to three delegates for the first 50 dues-paid active members and one additional delegate for each additional 50 active members or major fraction thereof, designating membership in the recognized component organization. MSHP members are encouraged to contact their assigned local association or regional society leadership to inquire about serving as a delegate.

Do I need to attend the ACE meeting to serve as a delegate?

You do not need to attend the ACE meeting to serve as a delegate. The Association historically offers free registration, which limits members to attending the HOD session. Delegates need to be physically present for the HOD session held during the ACE meeting to vote. Proxy votes are not permitted. If you volunteer to serve as a delegate, plan on being available to attend the session.  

Delegates serve for one year. They may be called upon to act on Association matters outside of the HOD session, such as approving a slate of candidates for executive board positions. This is typically done virtually.

Does MSHP caucus prior to the HOD Session?

Yes, the MSHP Organizational Affairs Committee is responsible for facilitating a meeting prior to the HOD session to discuss proposed resolutions and bylaw changes with the MSHP Board of Directors and delegates representing regional societies and local associations. If you are an MSHP member and represent a local association, it is recommended that you reach out to the Organizational Affairs chair to ensure that you are invited to the caucus meeting.

Where can I find more information regarding the MPA HOD?

The following resources provide more in-depth information regarding the HOD:

• MPA House of Delegates webpage
• MPA new delegate training video

Members can also pose additional questions to the MPA staff by emailing HoD@MichiganPharmacists.org.

References

• Michigan Pharmacists Association. House of Delegates. Available at: https://www.michiganpharmacists.org/house-of-delegates. Accessed on Sept. 17, 2024.
• Michigan Pharmacists Association. House of Delegates: New delegates and alternate delegates training [video]. Available at: https://www.youtube.com/watch?v=-V7S6RWx6Fc. Accessed on Sept. 17, 2024.

CE Speaking Opportunities at Non-Pharmacy Organizations

The MSHP Publications Committee was charged in 2024 with identifying opportunities for pharmacists to present at non-pharmacy organization meetings. After surveying MSHP membership in April, the committee compiled a list of organizations. Click the button below if you're interested in presenting.

OFFICERS

PRESIDENT | Kyle Schmidt | 616-685-6675 | Mercy Health St. Mary's, Grand Rapids

PRESIDENT-ELECT | Stacy Brousseau | 269-341-7407 | Bronson Methodist Hospital, Kalamazoo

IMMEDIATE PAST PRESIDENT | Michelle Dehoorne | 313-343-6381 | Ascension, Detroit

TREASURER | Marc Guzzardo | 810-606-6095 | Ascension, Detroit

EXECUTIVE VICE PRESIDENT | Edward Szandzik | 313-587-6279 | Detroit

DIRECTORS

Diana Kostoff | 313-725-7925 | Henry Ford, Detroit

Nada Farhat | nmhammou@med.umich.edu | Michigan Medicine, Ann Arbor

Julie Schmidt | 269-341-7999 | Bronson Methodist Hospital, Kalamazoo

Amber Lanae Martirosov | 313-916-3494 | Wayne State University, Detroit

REGIONAL SOCIETY REPRESENTATIVES 

CENTRAL | Tim Ekola | 734-845-3418 | VA Ann Arbor Healthcare System

NORTHERN | Miranda Maitland | mirandapmaitland@gmail.com | My Michigan Medical Center, Sault Ste. Marie

SOUTHEASTERN | Farzad Daneshvar | 248-910-2222 | AstraZeneca

WESTERN | Ben Pontefract | bpontefract@gmail.com | Ferris State University, Big Rapids

MANAGING EDITOR | Ryan Weiss | (517) 377-0232 | Michigan Pharmacists Association, Lansing

The MSHP Monitor is a publication of the Michigan Society of Health-System Pharmacists, published as a service to its members.

Michigan Society of Health-System Pharmacists - An Affiliated Chapter of the American Society of Health-System Pharmacists and a Practice Section of the Michigan Pharmacists Association